Incannex (IXHL) director reports 1,686,956-share RS grant
Incannex Healthcare (IXHL) reported a director’s Form 4 showing an acquisition of 1,686,956 shares of restricted common stock at $0 on November 14, 2025 under the company’s 2023 Equity Incentive Plan.
Rhea-AI Filing Summary
Incannex Healthcare (IXHL) reported a director’s Form 4 showing an acquisition of 1,686,956 shares of restricted common stock at $0 on November 14, 2025 under the company’s 2023 Equity Incentive Plan. The award vests in four tranches: 421,739 on December 10, 2025, 421,739 on June 30, 2026, another 421,739 on June 30, 2026, and 421,739 on June 30, 2027. Following the grant, the reporting person beneficially owns 1,957,803 shares, held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock, $0.0001 par value per share | 1,686,956 | $0.00 | $0.00 |
Footnotes (1)
- F1. Includes the following shares of restricted stock (the "Shares") granted on November 14, 2025, under the Issuer's 2023 Equity Incentive Plan, (i) 421,739 Shares that vest in full on December 10, 2025, (ii) 421,739 Shares that vest in full on June 30, 2026, (iii) 421,739 Shares that vest in full on June 30, 2026 and (iv) 421,739 Shares that vest in full on June 30, 2027.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Incannex (IXHL) disclose in this Form 4?
What is the director’s total beneficial ownership after the transaction?
What was the transaction code and price on the Form 4?
Which plan governs the IXHL restricted stock grant?
What is the issuer and ticker symbol referenced?
AI-generated analysis. How Rhea-AI works. Not financial advice.